SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma - Quaterly Results

07 Nov 2025 Evaluate
With no major difference for the quarter endedSeptember 2025 , the total revenue stood at Rs. 26087.80  millions.A slender decline of -25.18% was recorded to Rs. 4589.00  millions from Rs. 6133.50 millions in the corresponding previous quarter.Operating Profit reported a sharp decline to 7708.60 millions from 8709.70 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 26087.80 25441.80 2.54 51501.40 49568.00 3.90 94978.00 86292.50 10.07
Other Income 776.70 1074.80 -27.74 1418.90 2035.20 -30.28 4932.10 2705.00 82.33
PBIDT 7708.60 8709.70 -11.49 15081.50 15430.50 -2.26 30557.60 25367.90 20.46
Interest 1472.00 26.10 5539.85 2939.00 92.40 3080.74 3717.60 163.30 2176.55
PBDT 6236.60 8683.60 -28.18 12142.50 15338.10 -20.83 26840.00 25204.60 6.49
Depreciation 990.30 903.30 9.63 1959.60 1816.60 7.87 3780.10 3352.60 12.75
PBT 5246.30 7780.30 -32.57 10182.90 13521.50 -24.69 23059.90 21852.00 5.53
TAX 657.30 1646.80 -60.09 1466.30 2623.80 -44.12 4217.40 4125.70 2.22
Deferred Tax -318.10 322.60 -198.61 -430.50 213.70 -301.45 -481.90 12.40 -3986.29
PAT 4589.00 6133.50 -25.18 8716.60 10897.70 -20.01 18842.50 17726.30 6.30
Equity 412.80 400.60 3.05 412.80 400.60 3.05 412.60 400.60 3.00
PBIDTM(%) 29.55 34.23 -13.69 29.28 31.13 -5.93 32.17 29.40 9.44

Mankind Pharma Share Price

2078.75 24.65 (1.20%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×